Desonide foam: A review

Abstract

Desonide foam is a newly approved topical corticosteroid preparation of 0.05% desonide. It has been shown effective compared with vehicle placebo in the treatment of mild-to-moderate atopic dermatitis in both pediatric and adult populations. Given the favorable safety profile of all other desonide preparations and their utility as a low potency corticosteroid, desonide foam promises to be a useful addition to the armamentarium, when other desonide vehicles might be less acceptable.

Natural products to drugs: natural product-derived compounds in clinical trials

“…Ceftaroline acetate (PPI-0903, TAK-599) 27, which originally was discovered by Takeda, is being evaluated by Forest Laboratories in Phase II trials for the treatment of cSSSi and CAP. [117][118][119][120] The most advanced carbapenem is tebipenem pivoxil (ME-1211, L-084) 28, which is being evaluated in Phase III trials in Japan by Meiji Seika as a broad-spectrum antibiotic. [121][122][123] Tomopenem (CS-023, RO4908463, R1558, Daiichi Sankyo) 29 [124][125][126] and PZ601 (SM-216601, Protez, licensed from Dainippon Sumitomo) 30 127,128 are in Phase II trials, while ME-1036 (CP5609) (Forest and Meiji Seika) 31, is in Phase I evaluation.…”

Natural products as lead compounds in drug discovery

“…Other antibacterial agents under clinical development include Ceftaroline acetate 89, under Phase II clinical trials for the treatment of cSSSIs and CAP , which shows efficacy against the penicillin-resistant S. pneumonia [189]. Clinical trials with Tebipenem pivoxil 90, an oral carbapenem antibiotic, have been conducted by Meiji Seika in Japan, for treatment of otolaryngological/respiratory infections [190].…”